Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607218 | 0.88 | MEN1 (0.41) | AHRCYP2A6BRD4ENPP2ABL1 | |
| SCHEMBL15902097 | 0.86 | HDAC1 (0.40) | AHRNR4A2CYP2A6USP2GAA | |
| SCHEMBL15901906 | 0.83 | HDAC1 (0.44) | AHRNR4A2CYP2A6USP2GAA | |
| SCHEMBL25097633 | 0.78 | NOS1 (0.45) | GAABRD4MAOB | |
| SCHEMBL13836500 | 0.78 | AHR (0.42) | AHRNR4A2CYP2A6USP2GAA | |
| SCHEMBL12803946 | 0.77 | PRKCQ (0.30) | — | |
| SCHEMBL3350182 | 0.77 | KDR (0.52) | BRD4HDAC1ABL1 | |
| SCHEMBL3149877 | 0.76 | USP2 (0.50) | AHRNR4A2CYP2A6USP2GAA | |
| SCHEMBL1781944 | 0.76 | DUT (0.39) | ABL1 | |
| SCHEMBL27626299 | 0.76 | USP2 (0.53) | AHRNR4A2CYP2A6USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-1833824-B1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20140315956-A1 | SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF | NATIONWIDE CHILDREN'S HOSPITAL (US) | 2014-10-23 | — | — | US | disclosed |
| US-20090192155-A1 | Identification of Compounds Suitable for Treating Ad | MERCK SHARP & DOHME LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-7560481-B2 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1983979-A1 | IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD | Merck Sharp & Dohme Limited (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1851203-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007088400-A1 | IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBVIE INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2006086255-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315956-A1 | SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF | IL6, STAT3, JAK2 | AHR 353/4885NR4A2 2833/4885CYP2A6 214/4885 |
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | CNR2, CNR1, OPRL1 | AHR 266/4885NR4A2 593/4885CYP2A6 663/4885 |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | CNR2, CNR1, TRPV1 | AHR 1564/4885NR4A2 1088/4885CYP2A6 709/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | AHR 4398/4885NR4A2 3844/4885CYP2A6 3717/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | AHR 4398/4885NR4A2 3844/4885CYP2A6 3717/4885 |
| US-20090192155-A1 | Identification of Compounds Suitable for Treating Ad | PSEN2, MAPT, PSEN1 | AHR 3714/4885NR4A2 961/4885CYP2A6 2794/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | AHR 4398/4885NR4A2 3844/4885CYP2A6 3717/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | AHR 4398/4885NR4A2 3844/4885CYP2A6 3717/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | AHR 4398/4885NR4A2 3844/4885CYP2A6 3717/4885 |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | AHR 2219/4885NR4A2 3556/4885CYP2A6 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.